Mylan’s CEO, Robert Coury, is IMO a loose cannon. It would not surprise me if MYL’s Copaxone PR turned out to be a bluff for the benefit of Wall Street––i.e. a diversion from MYL’s self-inflicted balance-sheet woes.
It’s worth noting that MYL’s PR contained no mention of the financial terms between MYL and NATCO. Regards, Dew
Market Data 
Markets 
AI
